Sisignano, Marco
Baron, Ralf
Scholich, Klaus
Geisslinger, Gerd
Article History
First Online: 4 November 2014
Competing interests
: R.B. and G.G. are members of the IMI (Innovative Medicine Initiative of the EU) EuroPain collaboration, in which the following industry members are represented: Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Esteve, Gruenenthal, Pfizer, UCB Pharma and Sanofi Aventis. G.G. has received honoraria as a speaker from Gruenenthal, Mundipharma and Pfizer. He is a consultant for Abbvie. He has received research funding in the form of a grant from Mundipharma. R.B. has received honoraria as a speaker from Astellas, Bayer-Schering, Boehringer Ingelheim, Desitin, Eisai, Eli Lilly, Genzyme, Gruenenthal, Medtronic, Mundipharma, MSD, Pfizer, Sanofi Pasteur and Teva Pharma. He is also a consultant for Abbvie, Allergan, Astellas, AstraZeneca, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Genzyme, Gruenenthal, Medtronic, Merck, Mundipharma, Novartis, Pfizer and Sanofi Pasteur. He has received research funding in the form of grants from Genzyme, Gruenenthal and Pfizer. M.S. and K.S. declare no competing interests.